Skip to main
IMVT
IMVT logo

Immunovant Inc (IMVT) Stock Forecast & Price Target

Immunovant Inc (IMVT) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 43%
Buy 29%
Hold 29%
Sell 0%
Strong Sell 0%

Bulls say

Immunovant Inc. has demonstrated a significant potential in the treatment of autoimmune diseases, particularly through its lead candidate IMVT-1402, which has shown a sustained reduction in thyroid-stimulating hormone receptor autoantibodies (TRAb) during the off-treatment period. The data indicates an impressive responder rate of 81% among patients who did not respond to antithyroid drug therapy, aligning closely with the treatment's active phase responder rates of 70%-80%, thereby underscoring the therapeutic and disease-modifying capabilities of FcRn blockers in this patient population. This strong clinical performance highlights the durability of the treatment's effects, reinforcing a positive outlook on Immunovant's stock as it advances its innovative immunology solutions.

Bears say

Immunovant Inc operates in a competitive clinical-stage immunology market, focusing on developing IMVT-1402 to combat autoimmune diseases linked to elevated levels of pathogenic immunoglobulin G antibodies. However, high levels of thyrotropin receptor antibodies (TRAbs) have been correlated with increased relapse rates, indicating potential limitations in the efficacy of their product candidate. Additionally, the interconnectedness of TRAbs with TSHR and IGF-1R receptors may lead to severe complications, underscoring significant challenges in achieving therapeutic success and raising concerns about the company's future financial viability.

Immunovant Inc (IMVT) has been analyzed by 7 analysts, with a consensus rating of Buy. 43% of analysts recommend a Strong Buy, 29% recommend Buy, 29% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Immunovant Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Immunovant Inc (IMVT) Forecast

Analysts have given Immunovant Inc (IMVT) a Buy based on their latest research and market trends.

According to 7 analysts, Immunovant Inc (IMVT) has a Buy consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $31.57, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $31.57, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Immunovant Inc (IMVT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.